New funding for development of world's first lung cancer vaccine

Lung cancer cells look different from normal cells due to having “red flag” proteins called neoantigens. The LungVax vaccine will then activate the immune system to kill these cells and stop lung cancer. Getting the immune system to recognise and attack cancer is one of the biggest challenges in cancer research today. This research complements existing efforts through lung health checks to detect lung cancer earlier in people who are at greatest risk. President of CRIS Cancer Foundation, Lola Manterola, said: 'We are at a crucial moment in the history of cancer research and treatment.